تجاوز إلى المحتوى الرئيسي

بحث

عنوان الدراسة داعم الدراسة حالة الدراسة دواء الدراسة مرحلة الدراسة رقم بروتوكول الدراسة موقع الدراسة
A Phase 3 Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN) Janssen Research & Development Ongoing Nipocalimab 3 80202135EBF3001 King Faisal Specialist Hospital and Research Center (Riyadh), King Saud Medical City (Riyadh), King Fahad University Hospital (Al-Khobar)
A Phase 4, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Effectiveness and Safety of Tirzepatide Once Weekly in Adult Participants with Type 2 Diabetes during Ramadan (T-RAM) Eli Lilly Ongoing Tirzepatide 4 I8F-MC-GPIY 1-Al Moosa Specialized Hospital (al ahsa) 2-Dallah Hospital (Riyadh) 3-Saudi Airlines Medical Service Center (Jeddah) 4-King Fahad Medical City (Riyadh)
CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease Astrazeneca Ongoing Camizestrant (AZD9833) 3 8535C00001 King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab by subcutaneous injection in participants aged 18 years and older with moderate-to-severe atopic dermatitis (AD) who are on background topical corticosteroids and have had an inadequate response to prior biologic therapy or oral Janus Kinase (JAK) inhibitor treatment Sanofi Ongoing amlitelimab 3 EFC17599 King Faisal Specialist Hospital and Research Center (Riyadh)
Evaluating the efficacy and safety of Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine) in Newly Diagnosed Advanced Hodgkin Lymphoma Early Interim PET-Positive Patients; A Multi-Center, Open Label, Single Arm, Phase II, PET-Adaptive Study King Abdullah International Medical Research Center’s (KAIMRC) Ongoing Brentuximab Vedotin + AVD (Adriamycin, Vinblastine & Dacarbazine 2 RJ19/119/J King Abdullah Medical Complex (Jeddah)
A Randomized Controlled Trial Comparing Blood Glucose Control Intraoperative Between Insulin Drip vs. Insulin Boluses King Faisal Specialist Hospital and Research Center (Jeddah) Ongoing Insulin 3 2023-45 King Faisal Specialist Hospital and Research Center (Jeddah)
The ENERGY 3 Study: A Randomized, Controlled, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Children with Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency Inozyme Pharma, Inc Ongoing INZ701 3 INZ701-106 King Faisal Specialist Hospital and Research Center (Riyadh)
Long-term pain and adherence observational study for Endometriosis treatment Abbott Ongoing Duphaston 4 DYDR-522-0318 Dr.Arab Clinic
Real world Assessment of Dyslipidemia patients on Inclisiran effiCacy And toLerability: The RADICAL Study Novartis Ongoing LEQVIO 4 CKJX839A1S Dallah Hospital (Riyadh),International Medical Center (Jeddah), Armed Force Hospital (Tabuk) , My Clinic (Jeddah) Mouwasat Hospital (Dammam)
Effect of celecoxib on postoperative narcotic use and disease severity in patients with aspirin-exacerbated respiratory disease and chronic rhinosinusitis: a randomized controlled trial King Khalid University Hospital Ongoing Celecoxib 4 114809 King Khalid University Hospital (Riyadh) King Abdulaziz University Hospital (Riyadh)
عرض 31 - 40 من 482